Business Digest – Jan. 13, 2024

Business Digest – Jan. 13, 2024

North Dakota has been named one of the best states to start a business by Forbes Advisor for the second year in a row. The publication selected the state based on its business environment, low formation fees, business survival rate and lower cost of living, looking at a business’s ability to succeed, costs, workforce and … Read more

Natural supplements Guayusa tea and Lion’s Mane boost cognitive performance, study finds

Natural supplements Guayusa tea and Lion’s Mane boost cognitive performance, study finds

In a recent article published in the journal Nutrients, researchers assess the effects of AmaTea® Max (AMT) and Nordic Lion’s Mane (LM) on subjective cognitive perception and objective cognitive performance. Study: Acute Effects of Naturally Occurring Guayusa Tea and Nordic Lion’s Mane Extracts on Cognitive Performance. Image Credit: photo_gonzo / Shutterstock.com What are AMT and LM? AMT is made … Read more

Business Digest – Oct. 21, 2023

Business Digest – Oct. 21, 2023

Ministry on the Margins in Bismarck has won a “Bush Prize: North Dakota” from Strengthen ND and the Bush Foundation for its track record of successful community problem solving. The Bush Prize awards grant amounts up to 25% of an organization’s most recent fiscal year expenses, with a maximum of $500,000. BEK Communications Cooperative has been … Read more

Could a new framework for aging biomarkers revolutionize how we understand and treat the aging process?

Could a new framework for aging biomarkers revolutionize how we understand and treat the aging process?

In a recent review published in the journal Cell, a group of authors established a comprehensive framework for the terminology, characterization, and validation of aging biomarkers to facilitate their integration into clinical research and practice. Study: Biomarkers of aging for the identification and evaluation of longevity interventions. Image Credit: tomertu / Shutterstock Background Over time, organisms experience … Read more

New consensus statement provides guidance for use of 177Lu-PSMA radionuclide therapy in mCRPC patients

New consensus statement provides guidance for use of 177Lu-PSMA radionuclide therapy in mCRPC patients

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy. The statement, published in the July issue of The Journal of Nuclear Medicine, also reviews current clinical struggles … Read more